BELLE-2 is another trial that checks the efficacy of PI3K inhibitors—buparlisib with fulvestrant, again in case of postmenopausal women with hormone receptor-positive, HER2 negative advances breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.